Tango Therapeutics
The Associate Director, Pharmacovigilance Scientist at Tango Therapeutics leads safety surveillance and signal detection for oncology drug programs, authoring regulatory safety reports and guiding benefit‑risk assessments throughout the product lifecycle. The role collaborates cross‑functionally to ensure compliance with global PV regulations and supports both clinical development and post‑marketing activities.
Headquarters
Boston, Massachusetts, United States
Company Size
51-200 employees
Founded
2017
Tango Therapeutics is a precision oncology company that discovers and develops targeted cancer therapies by exploiting tumor-selective genetic vulnerabilities, especially via synthetic lethality approaches. The company combines functional genomics, computational biology, and a proprietary target-discovery platform to identify novel cancer targets and advance programs from discovery into the clinic. Tango focuses on genetically defined patient populations and partners with pharma to translate its discoveries into therapeutic candidates with the goal of delivering more effective, less toxic treatments.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Tango Therapeutics.
17% below the average for this role
Tango Therapeutics’ (TNGX) Sees Cautious Analyst Optimism Following Earnings
3 days ago
Scientist I
Makro Scientific
Director, Drug Safety & Pharmacovigilance Scientist
Dyne Therapeutics
Associate Director, Pharmacovigilance Scientist
Beeline Medicines
Senior Safety Scientist
Revolution Medicines
Senior Director, Patient Safety & Pharmacovigilance
Latigobio
Associate Director, PV Scientist
Praxis Precision Medicines, Inc.